Oxytocin C-terminal tripeptide is shown to be effective in treating human depression with greater efficacy and faster onset of action than traditional anti-depressants. Also, it is used in the synthesis of novel analogues to be tested for their ability to enhance the binding of [3H]-N-propylnorapomorphine to short isoform of human dopamine D2 receptors. References: Szabó G, Kovács GL, Baláspiri L, Telegdy G. D-pipecolyl-leucyl-glycinamide, a substituted tripeptide analogue of the C-terminal part of oxytocin, influences tolerance to and dependence on ethanol in mice. Alcohol Drug Res. 1987;7(2):99-105. PubMed PMID: 3778581.

纯度：≥98%

CAS：2002-44-0